Select clinical trials in myeloid malignancies evaluating oral HMAs in combination with cedazuridine
| Investigational agent(s) . | Patient population . | Trial number . |
|---|---|---|
| ASTX030 | MDS, CMML, AML | NCT04256317 |
| ASTX030 | MDS | NCT04608110 |
| ASTX727 | Lower-risk MDS | NCT03502668, NCT03906695 |
| ASTX727 | MDS with detectable MRD after allo-HCT | NCT04742634 |
| ASTX727 + itacitinib, INCB053914, or INCB059872 | MDS/MPN overlap syndromes | NCT04061421 |
| ASTX727 + venetoclax | MDS, CMML | NCT04655755 |
| ASTX727 + venetoclax | AML | NCT04657081, NCT04746235 |
| ASTX727 + venetoclax + ivosidenib or enasidenib | IDH1 or IDH2-mutated AML | NCT04774393 |
| ASTX727 + ASTX660 | AML | NCT04155580 |
| Investigational agent(s) . | Patient population . | Trial number . |
|---|---|---|
| ASTX030 | MDS, CMML, AML | NCT04256317 |
| ASTX030 | MDS | NCT04608110 |
| ASTX727 | Lower-risk MDS | NCT03502668, NCT03906695 |
| ASTX727 | MDS with detectable MRD after allo-HCT | NCT04742634 |
| ASTX727 + itacitinib, INCB053914, or INCB059872 | MDS/MPN overlap syndromes | NCT04061421 |
| ASTX727 + venetoclax | MDS, CMML | NCT04655755 |
| ASTX727 + venetoclax | AML | NCT04657081, NCT04746235 |
| ASTX727 + venetoclax + ivosidenib or enasidenib | IDH1 or IDH2-mutated AML | NCT04774393 |
| ASTX727 + ASTX660 | AML | NCT04155580 |
MPN, myeloproliferative neoplasm; MRD, minimal residual disease.